Peter George
Chairman
Healthcare
CLC Bio
Australia
Biography
Peter George joined Ergomed as a non-executive director in May 2014 and has over 20 years’ experience in the pharmaceutical services industry. Peter stepped down as Chief Executive Ofï¬cer of Clinigen Group plc (AIM: CLIN) at the end of 2016. He started Clinigen in 2010 as a global specialty pharmaceuticals and pharmaceutical services business and by 2016 it had a c.£1bn market cap, being one of the most successful recent floats on AIM. Peter remains as Non-Executive Director at Clinigen. Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management buy-out in 2007. Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Paciï¬c regions. Peter has also held roles as the Chief Operating Ofï¬cer of Unilabs Clinical Trials International Limited, and Head of Clinical Pathology NHS. Peter is also Chairman of Wichtig International, Mitre Grou
Research Interest
Peter George joined Ergomed as a non-executive director in May 2014 and has over 20 years’ experience in the pharmaceutical services industry. Peter stepped down as Chief Executive Ofï¬cer of Clinigen Group plc (AIM: CLIN) at the end of 2016. He started Clinigen in 2010 as a global specialty pharmaceuticals and pharmaceutical services business and by 2016 it had a c.£1bn market cap, being one of the most successful recent floats on AIM. Peter remains as Non-Executive Director at Clinigen. Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management buy-out in 2007. Before this, Peter was executive Vice President for Wolters Kluwer Health with responsibility for Europe and Asia Paciï¬c regions. Peter has also held roles as the Chief Operating Ofï¬cer of Unilabs Clinical Trials International Limited, and Head of Clinical Pathology NHS. Peter is also Chairman of Wichtig International, Mitre Grou
